Most life sciences organizations didn’t put “rethink our CRM platform” on their strategic agenda for the year. The Veeva Salesforce split put it there anyway.
And for a lot of these organizations, it’s not a small thing to work through. It’s not just a version upgrade or a feature migration. It’s a change to the foundation that their data runs on. The effects of this split can compound rather quickly if an organization isn’t aware of what they mean.
As they said during the initial announcement, Veeva CRM on Salesforce is supported through September 2030. Most teams hear that and feel like they have plenty of time. What they actually have is a window, and it closes faster than it looks once you account for all the requirements needed. Think evaluation cycles, alignment with functions, and the basic reality that rebuilding data infrastructure on a deadline is tough.
The organizations that navigate this well won’t be the ones that started scrambling in 2028 or 2029, they’ll be the ones that use these next 12-18 months to get their data architecture in order. A migration plan matters. The companies that come through this split in the best shape are the ones that treat it as a data ownership problem from the start, not just a software one.
What is the Veeva Salesforce Split and Why Does It Matter for Life Sciences?
The History of the Veeva and Salesforce Partnership
For quite a while, Veeva CRM on Salesforce worked well for teams in the life sciences space. On one side, you had Veeva, which brought the expertise in areas like call reporting, sample management, and territory management. On the other side, Salesforce provided the infrastructure that IT teams already trusted. It was a productive pairing that served a lot of organizations well.
That pairing changed when Veeva decided its long-term future didn’t need to run on another platform, and so Vault CRM was born. Veeva Vault runs on its own infrastructure, and that’s where new customers start today. The Salesforce product may stay supported through 2030, but the product momentum has shifted.
Key Reasons Behind the Veeva Announced Separation
From Veeva’s perspective, the logic is straightforward. Owning the full stack means owning the roadmap, release cycle, the data model, and the integration story across its product suite. Everything that Veeva builds can now share a single infrastructure. That’s a meaningful advantage for them.
For customers, the implications run deeper than a platform swap. The infrastructure underneath a CRM shapes how every integration behaves or how data moves across the organization. When that foundation is changed, you’re not just swapping software. You’re touching everything built on top of it.
Critical Timeline: September 2025 to 2030 Transition
September 2025 got a lot of attention as a key milestone date. The actual support deadline is 2030, but “supported until 2030” and “comfortable until 2030” are different things. Large life sciences organizations typically need 18-36 months to get through a compliant platform migration, and that timeline doesn’t include validation requirements. If you start that clock today, 2030 comes a lot faster than it looks.
The transition clock is running. Your data strategy should be too.
GRAX replicates your Salesforce data in near real-time to your own cloud — so you own it no matter where the platforms land.
What Actually Changes for Life Sciences Companies
What “Decoupling” Means in Practice
Decoupling from Salesforce means Veeva’s CRM runs on Vault infrastructure. This means new customers will start out on Vault, while existing customers have a couple of options. They can either follow Veeva to Vault, move to a Salesforce-native alternative, or take a hybrid approach during the transition time period. Each of these choices means rethinking things like integrations and data ownership. A lot of organizations may find that the right decision for them may take some time to figure out.
Impact on CRM Architecture and Data Models
Life sciences organizations don’t run their CRM in isolation. Things like ERP systems, data warehouses, analytics platforms, and their medical information systems all connect to their CRM in some form or another. When the platform underneath changes, those connections need to be re-evaluated, and many will have to be rebuilt from scratch.
What Happens to Existing Salesforce-based Customers
No one is being forced to an immediate cutover. But the transition clock is ticking, and the guidance is consistent regardless of which path an organization ultimately chooses. Start the data architecture review now, because the organizations that do are the ones who get to make deliberate decisions. The ones that wait will be making reactive ones.
How Will the Veeva Salesforce Split Impact Your CRM Solution?
Comparing Veeva CRM to Salesforce Life Sciences Cloud
For some organizations, this transition isn’t just about migration. It’s about whether to follow Veeva at all. Salesforce Life Sciences Cloud has matured considerably, and for organizations with deep Salesforce investments, staying in that ecosystem may be the most strategic long-term path.
That reframes the question entirely. Instead of “how do we move to Vault?” it becomes “which platform will best serve our organization?” That’s a harder question to ask, but it’s the right one. Defaulting to the path of least resistance can often lead to regret.
Understanding Platform Changes and Functionality Differences
Vault CRM is purpose-built for the life sciences space. It’s designed to work tightly with the rest of Veeva’s product suite, which is genuinely valuable for organizations that rely on that integration story.
Salesforce Life Sciences Cloud is a different kind of bet. It’s a broader platform with more customizations and a larger partner ecosystem behind it. It basically trades vertical depth for platform breadth.
Neither is automatically the right choice. The best fit depends on your existing integrations, IT environment, compliance needs, and what your team needs the platform to handle day to day.
What Changes Operationally for Pharma and Biotech Teams
Multiple teams, whether that’s operations, field, or IT, depend on CRM workflows in one way or another. When the platform underneath those workflows changes, the surface experience can still look familiar long after the underlying systems have changed. That gap between what end users see versus what has actually changed is exactly where migration risks grow. It’s worth noting that this isn’t just an IT problem; it’s a business transformation that IT happens to be running.
Platform changes shouldn’t put your data at risk.
GRAX keeps a complete, schema-intact copy of your Salesforce data in your own infrastructure, independent of whatever CRM decision you make next.
Veeva CRM vs. Salesforce Life Sciences Cloud: Key Differences
Platform Architecture
The main difference between Veeva and Salesforce’s solutions is easy to understand. Veeva CRM runs on Veeva Vault, while Salesforce Life Sciences Cloud runs on Salesforce. That single difference dictates how your data moves across systems and even how it connects to other tools your organization might be using.
Ecosystem and Integrations
Salesforce brings with it a larger partner ecosystem. It has the AppExchange as well as years of established integrations across virtually every industry. Veeva brings with it a deep life sciences specialization and native alignment across all its products.
Therefore, the better fit depends on which ecosystem your tech stack lives in. Organizations that have built significant infrastructure on Salesforce may face switching costs by moving to Veeva Vault. On the other hand, organizations whose tech stack is heavily Veeva-aligned face similar issues if they stay on Salesforce.
Flexibility vs. Specialization
The core trade-off of the Veeva Salesforce split is whether to prioritize broader platform flexibility or purpose-built functionality for life sciences operations. That had already been a defining question in the industry for years, and the split just forces organizations to definitively answer it.
Organizations with complex architectures, especially if their Salesforce data feeds a larger strategy, tend to weigh platform flexibility more heavily. On the other hand, organizations running deeply integrated Veeva suites tend to find Vault CRM’s story more compelling.
Cost and Vendor Lock-in Implications
Licensing cost is usually the first number an organization looks at, but this rarely tells the full story. Migration services, rebuilds, retraining, reporting, you name it, all carry considerable costs. The platform with lower licensing fees can end up carrying higher total implementation costs, and that tradeoff should be taken into consideration.
From the vendor lock-in standpoint, every organization creates dependencies, and the goal isn’t to avoid them entirely. The goal is to preserve access to your own data, no matter what happens to the vendor. Data that only exists inside a vendor’s interface isn’t data that your organization actually controls. And that’s a distinction that matters in regulated industries like life sciences.
The Biggest Risk Nobody Talks About: Your Data
What Happens to Historical CRM Data During the Split
Here’s the pattern that plays out in platform migrations across industries, and life sciences is no exception. Active records and current workflows get carefully planned for. But historical data gets treated as a secondary concern until someone in a meeting inevitably asks a question about it.
Historical CRM data isn’t just archival noise. It’s the foundation for things like territory planning, trend analysis, forecasting, compliance, and operational decisions that your team makes every week. It can’t just be reconstructed after the fact. Once access to it is broken, the downstream effects show up in almost every aspect of your business. That means audits, reports for leadership, and even in AI models that are supposed to be learning from your organization’s full history.
Risk of Data Fragmentation Across Systems
Data rarely moves cleanly in a platform migration. Some records migrate, while others stay behind. Some get rebuilt in structures that may look similar but aren’t. When this happens, reporting logic gets recreated, and the errors are hard to spot until someone runs a comparison. The result is predictable: you get a period where no one trusts the data. Your reports get questioned, and leadership stops relying on dashboards to get the numbers they need. That erosion of data trust is hard to rebuild and usually takes longer to recover from than the migration itself.
Reporting Inconsistencies and Loss of Context
A dashboard showing this quarter’s performance only means something if the methodology behind it is consistent with last quarter, the quarter before, and so on. When field mappings shift and reporting logic shifts during a migration, that consistency breaks. Teams lose the ability to compare current performance with historical baselines. A product launch that looks like it’s tracking well might be tracking against data that no longer matches how previous ones were measured. For teams that make decisions based on trend lines, that becomes a huge problem.
Compliance and Audit Risks (GxP, FDA)
FDA and GxP requirements don’t make exceptions for platform migrations. Regulators expect clear, defensible, and continuous records to be kept. A migration that moves current data forward cleanly but leaves historical records fragmented or inaccessible can create audit exposure.
Compliance needs to be a part of the equation from the very beginning when considering which approach to take for the Veeva Salesforce split. Otherwise, you risk discovering issues at the validation stage of your migration that lead to expensive delays.
Historical data doesn’t migrate itself. Plan for it now.
GRAX preserves your full data history for reporting, compliance, and AI regardless of which platform you’re on.
What Are the Data Migration and Integration Challenges After the Veeva Split?
Migration From Salesforce Platform to Vault CRM: What Breaks
When it comes to a migration, the part that usually works is the records moving. What tends to break is everything attached to the records. Workflows, permissions, and integrations – none of that migrates automatically. Some can be rebuilt, but some will have to be designed from scratch in the context of a different data model.
Integration Requirements Between Veeva Vault and Veeva CRM
Every system currently integrated with Salesforce-based Veeva CRM needs to be reassessed when moving to Vault. That means ERP connections, data warehouse feeds, analytics platform integrations, and any custom integrations built by internal teams. None of them should be assumed to carry over without proper testing.
Why “Lift and Shift” Approaches Fail
The lift-and-shift assumption is that two platforms are similar enough to move data with minimal transformation. In complex environments, that assumption is almost always wrong. Platform differences mean records can arrive in the destination structurally correct but functionally wrong. What ends up happening are things like reports that don’t run and workflows that won’t trigger. The migration technically succeeded but the system doesn’t work.
Hidden Cost of Re-Mapping Data and Workflows
Organizations often underestimate the cleanup work that follows a migration. Rebuilding process logic, validating that reports are giving accurate results, and retraining teams on new interfaces. This type of work takes longer than the migration scope suggests and costs more than the migration budget anticipates. The organizations that plan for it explicitly are the ones that don’t have to adjust their budget in the middle of the project.
How Will AI and Innovation Change in Life Sciences CRM Post-Split?
Why AI Depends on Historical and Structured Data
AI models are only as useful as the data behind them. Take, for example, a forecasting model trained on two years of complete, structurally sound CRM history. It’s going to produce much better results than one trained on a partial dataset with a migration gap in the middle. In a regulated environment, having different outputs is a compliance and operational risk.
For life sciences organizations investing in AI, CRM data quality isn’t just a governance priority that exists on its own roadmap. It’s a direct prerequisite that has to happen from the beginning.
AI Capabilities in Veeva Systems Versus Salesforce
Both platforms are investing heavily in AI. Veeva is building capabilities into Vault CRM designed specifically for life sciences commercial workflows. Salesforce is embedding AI across its platform through Einstein and Agentforce.
The platform-level AI roadmap comparison matters less than most organizations think at this stage. The better question is whether the underlying data is complete, accessible, and structured enough to support AI use cases. An AI feature set built on data that was damaged during a migration produces results that can’t be used by anyone.
Risks of Losing Historical Context During Migration
Historical context is what separates useful AI from noisy AI. Think of it this way: trend analysis requires trend data. Forecasting models need historical baselines to work effectively. Comparative reporting depends on continuity across time periods. When that history is lost or degraded during a migration, even just a tiny bit, the analytical work that depends on it is degraded too, often in ways that build up over time.
What “AI-Ready Data” Actually Requires
Data should be complete, consistently structured, and historically preserved. It should be accessible outside of the platform that created it without needing custom extraction work every time someone needs it. Most importantly, it should be governed well enough that the people using it for analytics and AI can trust what they’re working with.
None of that happens automatically after a migration. It comes from deliberate data architecture decisions made before the move begins. That’s why organizations that treat data strategy as a cleanup for later often end up rebuilding it under much tougher conditions.
What Should Pharmaceutical Companies Consider When Choosing a Vendor?
Comparing Veeva CRM and Salesforce Life Sciences Cloud Features
Feature comparisons are useful but they’re also the easiest part to get wrong. Surface-level feature parity between two platforms can mask meaningful architectural differences underneath. Here’s where the two actually differ in ways that matter for life sciences commercial teams.
Vault CRM was built specifically for life sciences. It comes with native support for things like inquiry management, sample management, and call recording. It connects natively to Veeva’s other products, which matters significantly for organizations that have commercial and clinical data that need to be able to talk to each other.
Salesforce Life Sciences Cloud brings a different set of strengths. Since it runs on the broader Salesforce platform, it has much tighter integration with tools like Slack, Tableau, and Mulesoft. Its AI and agentic roadmap is also moving incredibly fast through Einstein and Agentforce. For organizations using Salesforce more broadly, the platform architecture has more natural support.
The differences between these two that can catch a lot of organizations off guard are the ones that don’t show up in a standard comparison chart. Vault CRM won’t require the same level of custom configuration that Salesforce implementations often do. Salesforce offers more flexibility, but that often comes with more configurations to maintain.
A more useful way of evaluation is to compare both platforms against your actual commercial workflows and your long-term product roadmap requirements. Don’t just look at a checklist of things your team may or may not even use.
Regulatory and Compliance Requirements for Life Sciences Organizations
If you’re about to start a platform evaluation, things like retention periods, audit trail requirements, and controlled access need to be front-loaded into the process because they constrain the decision in ways that aren’t always visible from the feature list. Any vendor claiming a smooth path to validation without addressing these specifics upfront deserves more scrutiny, not less.
Total Cost of Ownership and Long-Term Flexibility
When you’re planning what to do for the Veeva Salesforce split, model a five-year total cost picture, not just year-one licensing. Include migration services, integration rebuild costs, validation work, retraining, and the internal resource time required to manage the transition. As we said above, the platform with the lower licensing cost can often carry higher implementation costs, and that tradeoff needs to be considered.
Vendor Lock-in and Ecosystem Dependencies
The lock-in question looks different depending on which direction you’re moving. Organizations following Veeva to Vault CRM are trading one set of dependencies for another, but within a more controlled environment where Veeva owns the whole stack. Organizations staying in Salesforce retain platform flexibility but need to think carefully about how their Salesforce data connects to the rest of their technology.
The practical question to test in either scenario is this: if the vendor relationship changed tomorrow, how quickly could your organization get access to its full data history, in a usable format, without the vendor’s involvement? For most organizations that haven’t thought this through, the honest answer is “not quickly.” In life sciences, data can shift in an instant due to regulatory demands so the risk is worth quantifying before it becomes a problem.
Your Strategic Options: Stay, Migrate, or Hybrid
Moving Fully to Veeva Vault CRM
For organizations that depend on Veeva’s broader product suite, a full move to Vault CRM is probably the best long-term path. The integration story is strongest within the Vault ecosystem, and organizations will find the internal case easier to make and transition more tractable.
Returning or Moving to Salesforce Ecosystem
For organizations with deep Salesforce investments including things like complex integrations built on Salesforce APIs or alignment with Salesforce’s AI roadmap, this transition is a real opportunity to evaluate whether staying in that ecosystem is the right long-term call. That’s not a fallback position. For a number of organizations, it might be the correct choice.
Hybrid Approach During Transition
For large enterprises that can’t execute a clean cutover without serious operational disruption, a phased hybrid model is the most realistic near-term path. Running parallel environments creates complexity and cost, and it also creates the continuity that commercial teams and compliance functions need during the transition period. The discipline is treating the hybrid phase as a defined, time-bounded bridge and not letting it become a permanent state because the clean cutover never quite gets scheduled
How Can Life Sciences Companies Prepare for the Veeva–Salesforce Split?
Creating a Transition Roadmap for Your CRM Solution
A complete roadmap covers systems, data, integrations, reporting, compliance obligations, and historical data ownership, with named owners, defined decision points, and validation time built in for regulated systems. It should also include a clear definition of what “done” means for data continuity, not just platform cutover. Those are different milestones, and the gap between them is where post-migration problems tend to live.
Audit of Current Salesforce and Veeva Data Footprint
Know what you have before deciding what to do with it. A full inventory of what data lives where, how it’s structured, what systems depend on it, and what retention and access requirements apply is the foundation everything else gets built on. Organizations that skip this step run into gaps mid-migration at the worst possible time.
Identifying Critical Reports and Dependencies
Map the dashboards, reports, and connected workflows that commercial, analytics, compliance, and field teams use regularly. Identify which ones depend on historical data and which require cross-system joins. These are the highest-risk items in any migration and deserve the most explicit planning, not because they’re technically the hardest, but because their failure is the most visible to the business.
Key Considerations for Pharmaceutical Workflow Continuity
Field team workflows, sample management processes, call reporting, and HCP engagement tracking all depend on CRM continuity. Each should have a named owner in the transition plan and a defined validation process before any live data is moved. IT cutover dates don’t capture this. The continuity that matters is the continuity experienced by the people running commercial operations on the day the switch happens.
Best Practices for Managing Change in Life Sciences Cloud Environments
The transitions that go poorly almost always share one thing in common: decisions that should have been made in month two got made in month fourteen, under pressure, with less information than was available earlier. The ones that go well aren’t necessarily smoother or better resourced, they’re just more honest upfront about how much work will be required.
How to Protect Your Data During the Transition
Why Native Tools Are Not Enough
Platform-native migration and export tools can certainly move records. But they don’t solve the harder problems: maintaining continuity, preserving version history, keeping archived data accessible, and giving your organization independent access to its own data.
Those harder problems are the ones that show up in audit findings and leadership escalations. Point blank, native tools are designed for migration, not data governance.
Importance of Independent Data Storage and Recovery
Independent data storage means your organization controls the three Rs: retention, recovery, and reporting, regardless of what’s happening with the CRM. During a transition, independence isn’t just a “nice to have,” it’s a necessity. It’s what keeps your compliance intact and your historical data accessible while everything else is changing.
Preserving Full Historical Context Across Platforms
Moving current records without preserving version history produces a migration that’s technically complete and operationally incomplete. The difference between those two outcomes doesn’t usually surface until someone tries to pull a report that uses data that’s no longer accessible. By then, the migration is done and the data is gone.
Ensuring Auditability and Compliance
Audit readiness should be part of your initial design input, not just a post-migration verification. That means knowing which records carry retention requirements, how change history will be preserved, how user access will be handled, and how your organization will show regulators that the data integrity is intact. Building those answers into the transition plan from the start is a lot less expensive than building them afterward.
Leverage GRAX for a Smooth Transition
For life sciences organizations working through the Veeva Salesforce split, GRAX replicates Salesforce in near real-time to your own infrastructure. That can be your own cloud environment, like AWS, Azure, or Google Cloud, or an on-prem location of your choosing. GRAX preserves schema fidelity while ensuring your CRM data remains accessible for things like reporting, compliance, and AI use cases.
Rather than treating this transition as purely a migration problem you need to solve, it’s best to use this moment to build a data foundation you can actually own. One that’s independently governed, fully accessible, and ready for the investments ahead.
Native export tools move records. They don’t govern data.
GRAX gives your organization independent access to its Salesforce data, with version history, schema fidelity, and no dependency on Veeva or Salesforce to retrieve it.
FAQs
What happens to Veeva CRM data on Salesforce?
It’s fully supported until 2030 for existing customers. Vault CRM is Veeva’s platform for new customers, and the direction where roadmap investment is headed.
Can you keep historical Salesforce data after moving to Vault?
Yes, but it requires a deliberate data retention and archiving strategy. Historical data doesn’t automatically migrate with the same structure and accessibility it had in the original platform. Without specific planning and tooling it won’t come with you intact.
Is Salesforce Life Sciences Cloud a replacement for Veeva?
For some organizations, it is, for others, no. Whether it’s the right replacement depends on your integration footprint, compliance requirements, and long-term platform strategy. It’s worth a real evaluation instead of a default assumption.
How long will the transition take?
For most large life sciences organizations, this is a multiyear process that should be taken seriously. The scope of integrations, validation requirements for regulated systems, and the complex nature of historical data migration all considerably extend the timeline. Organizations that plan for 18 months may find themselves looking at a 30-month process instead.
What are the biggest risks during migration?
The biggest risks your organization faces include things like loss of access to historical data, fragmented reporting that erodes trust, and broken integrations you have to rebuild. There’s also a huge risk of compliance gaps from incomplete audit trails. Make sure to have a good understanding of the business process dependencies that don’t often show up until something breaks.
